RLMD
HealthcareRelmada Therapeutics, Inc. · Biotechnology · $520M
What is Relmada Therapeutics, Inc.?
Relmada Therapeutics is a clinical-stage biotechnology company focused on developing treatments for central nervous system diseases. Headquartered in Coral Gables, Florida, the company is advancing a lead drug candidate through late-stage clinical trials.
Relmada generates no commercial revenue yet — it is a pre-revenue, clinical-stage company. Its business model centers on advancing its lead candidate, Esmethadone (REL-1017), through Phase 3 clinical trials targeting major depressive disorder in adults. If approved, Esmethadone would be positioned as both an adjunctive and monotherapy treatment. The company funds operations primarily through capital markets activity while pursuing regulatory milestones that could unlock future commercialization.
Relmada Therapeutics was founded in 2014 and is headquartered in Coral Gables, Florida.
- Esmethadone (REL-1017) — NMDA receptor antagonist for major depressive disorder
- Phase 3 clinical program for adjunctive and monotherapy MDD treatment
- CNS disease pipeline targeting unmet psychiatric needs
Is RLMD a Good Stock to Buy?
UQS Score rates RLMD as Poor overall, reflecting the significant challenges typical of pre-revenue clinical-stage biotechnology companies.
Among the five pillars, Risk stands out as the relative bright spot — suggesting the company's near-term financial structure carries somewhat less immediate distress than its overall profile might imply. This is notable for a clinical-stage biotech where cash runway and balance sheet management are critical.
Quality, Moat, and Growth all register as Weak, consistent with a company that has no approved products, no recurring revenue, and an unproven competitive position. Valuation is rated Elevated, meaning the market is pricing in considerable future success that remains uncertain.
See the full pillar breakdown and underlying financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does RLMD pay dividends?
No — Relmada Therapeutics, Inc. does not currently pay a dividend.
Relmada Therapeutics does not pay a dividend, which is standard for clinical-stage biotechnology companies. All available capital is directed toward funding clinical trials and advancing Esmethadone toward potential regulatory approval. Income-focused investors should not expect distributions from RLMD in the near term.
When does RLMD report earnings?
Relmada Therapeutics reports financial results on a quarterly cadence, consistent with US-listed public companies.
As a pre-revenue company, quarterly reports focus on cash position, operating expenses, and clinical trial progress rather than sales or profitability. Key updates typically center on trial enrollment, regulatory interactions, and capital runway rather than traditional earnings metrics.
For the most recent quarter's results and clinical updates, visit Relmada Therapeutics' investor relations page directly.
RLMD Price History
+3.2% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Relmada Therapeutics, Inc.?
Based on Relmada Therapeutics, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
RLMD Long-term Outlook
The fundamental outlook for RLMD is binary in nature — heavily dependent on Phase 3 clinical outcomes and subsequent regulatory decisions for Esmethadone. The Weak Growth pillar reflects the absence of near-term revenue visibility, while the Good Risk rating suggests the company has managed its financial structure with some discipline. The Elevated Valuation pillar indicates the current market price embeds meaningful optimism about trial success, which introduces downside risk if clinical results disappoint.
Growth drivers
- Positive Phase 3 trial readouts for Esmethadone in major depressive disorder
- Potential regulatory approval opening a large, underserved CNS market
- Licensing or partnership deals that could validate the pipeline
Key risks
- Clinical trial failure or unexpected safety findings for REL-1017
- Elevated valuation leaves limited margin of safety if milestones slip
- Ongoing cash consumption with no commercial revenue to offset costs
RLMD vs Peers
Relmada operates in a crowded clinical-stage biotech landscape alongside other pre-revenue companies pursuing novel therapeutic targets.
Absci focuses on AI-driven drug creation and protein design rather than traditional CNS pharmacology, representing a different technological approach to drug development.
Tectonic Therapeutic pursues engineered receptor pharmacology across multiple disease areas, differentiating itself from Relmada's singular CNS depression focus.
Immix Biopharma targets oncology and inflammatory diseases, giving it a distinct therapeutic focus compared to Relmada's CNS-only pipeline.
Frequently Asked Questions
What does Relmada Therapeutics do?
Relmada Therapeutics is a clinical-stage biotechnology company developing treatments for central nervous system diseases. Its primary focus is Esmethadone (REL-1017), an NMDA receptor antagonist currently in Phase 3 trials for major depressive disorder in adults. The company has no approved products or commercial revenue at this time.
Does RLMD pay dividends?
No, Relmada Therapeutics does not pay a dividend. As a pre-revenue clinical-stage company, it directs all available capital toward funding clinical development. Dividend payments are not typical for companies at this stage of development.
When does RLMD report earnings?
Relmada reports on a standard quarterly cadence. Because it is pre-revenue, reports focus on cash runway, operating expenses, and trial progress. For exact reporting dates, check the investor relations section of the company's official website.
Is RLMD a good stock to buy?
UQS Score rates RLMD as Poor overall. The rating reflects weak Quality, Moat, and Growth pillars alongside an Elevated Valuation. The relative strength in the Risk pillar offers some nuance, but the overall profile signals significant uncertainty. Investors should review the full analysis before drawing conclusions.
Is RLMD overvalued?
The UQS Valuation pillar for RLMD is rated Elevated, meaning the current market price appears to embed considerable optimism about future clinical and regulatory success. For a pre-revenue biotech, this creates meaningful downside risk if key milestones are not met on schedule.
How does RLMD compare to its competitors?
Relmada competes in the clinical-stage biotech space alongside companies like Absci, Tectonic Therapeutic, and Immix Biopharma. Each pursues different therapeutic areas and technologies. UQS Score provides side-by-side pillar comparisons for Pro members to evaluate relative quality across these peers.
What is RLMD's market cap bracket?
Relmada Therapeutics is classified as a small-cap company. This places it in a segment of the market that typically carries higher volatility and liquidity risk compared to mid-cap or large-cap peers, which is common among clinical-stage biotechnology firms.
Who founded Relmada Therapeutics?
Relmada Therapeutics was founded in 2014. Founding details and leadership history are publicly available through the company's official filings and investor relations materials for those seeking a complete corporate history.
Is RLMD a long-term quality investment?
From a long-term quality perspective, RLMD's UQS profile presents challenges. Weak Quality, Moat, and Growth pillars indicate the company has not yet demonstrated the durable fundamentals typically associated with long-term compounders. Its trajectory depends almost entirely on clinical and regulatory outcomes for Esmethadone.
What is the main competitive advantage of Relmada Therapeutics?
Relmada's potential advantage lies in Esmethadone's novel mechanism of action as an NMDA receptor antagonist for depression — a target with limited approved competition. However, the UQS Moat pillar is rated Weak, reflecting that this advantage is unproven commercially until regulatory approval is secured.
What sector does RLMD belong to?
Relmada Therapeutics operates in the Healthcare sector, specifically within clinical-stage biotechnology. It focuses on central nervous system diseases, a therapeutic area with high unmet need but also high clinical and regulatory risk.
Is RLMD a growth stock or value stock?
Based on its UQS profile, RLMD does not fit neatly into either category. The Growth pillar is rated Weak due to the absence of revenue, while the Valuation pillar is Elevated — meaning investors are paying a premium for speculative future outcomes rather than current fundamentals.
Unlock Full RLMD Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View exact UQS pillar scores across all five dimensions
- ✓Access detailed financial metrics and trend data
- ✓Compare RLMD side-by-side with clinical-stage peers
- ✓See the complete risk and valuation breakdown
- ✓Track score changes as new data becomes available
- ✓Filter small-cap biotech stocks by quality pillar strength
Pro Analysis
RLMD — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| Apr 22, 2026 | 17.2 | 0.0 | 9.0 | 18.5 | 74.7 | 0.0 | -0.9 |
| Apr 14, 2026 | 18.1 | 0.0 | 9.0 | 23.1 | 74.7 | 0.0 | -10.2 |
| Apr 13, 2026 | 28.3 | 0.0 | 50.0 | 23.1 | 74.7 | 0.0 | +10.2 |
| Apr 2, 2026 | 18.1 | 0.0 | 9.0 | 23.1 | 74.7 | 0.0 | — |
RLMD — Pillar Breakdown
Quality
— 0.0/100 (25%)Relmada Therapeutics, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Free cash flow relative to market value.
Growth
— 18.5/100 (20%)Relmada Therapeutics, Inc. faces growth headwinds with declining or stagnant revenue trends.
Revenue trajectory over the last twelve months.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 73.8/100 (15%)Relmada Therapeutics, Inc. maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)Relmada Therapeutics, Inc. appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 9/100 (25%)Relmada Therapeutics, Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for RLMD.
Score Composition
Financial Data
More Stock Analysis
How is the RLMD UQS Score Calculated?
The UQS (Unified Quality Score) for Relmada Therapeutics, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Relmada Therapeutics, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Relmada Therapeutics, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.